Ascendis Pharma A/S (NASDAQ:ASND) had its price objective boosted by equities research analysts at Wells Fargo & Co from $83.00 to $88.00 in a research report issued on Thursday, The Fly reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Wells Fargo & Co’s target price indicates a potential upside of 24.13% from the company’s current price.

Other research analysts have also issued research reports about the stock. Stifel Nicolaus dropped their price objective on shares of Ascendis Pharma A/S from $85.00 to $81.00 and set a “buy” rating for the company in a report on Thursday. ValuEngine upgraded shares of Ascendis Pharma A/S from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 2nd. Leerink Swann restated a “market perform” rating and set a $70.00 price target (up previously from $64.00) on shares of Ascendis Pharma A/S in a report on Thursday, May 31st. Wedbush restated an “outperform” rating and set a $76.00 price target on shares of Ascendis Pharma A/S in a report on Tuesday, May 15th. Finally, BidaskClub lowered shares of Ascendis Pharma A/S from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 7th. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $76.88.

NASDAQ ASND traded up $0.20 during trading hours on Thursday, reaching $70.89. The company’s stock had a trading volume of 11,188 shares, compared to its average volume of 125,257. The firm has a market cap of $3.13 billion, a PE ratio of -16.37 and a beta of 0.67. Ascendis Pharma A/S has a 52 week low of $26.30 and a 52 week high of $76.99.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Wednesday, May 30th. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.38). The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.30 million. Ascendis Pharma A/S had a negative net margin of 12,089.94% and a negative return on equity of 64.87%. analysts predict that Ascendis Pharma A/S will post -4.36 EPS for the current year.

Several large investors have recently added to or reduced their stakes in ASND. Alps Advisors Inc. grew its position in Ascendis Pharma A/S by 21.0% in the 1st quarter. Alps Advisors Inc. now owns 48,775 shares of the biotechnology company’s stock valued at $3,190,000 after purchasing an additional 8,478 shares during the period. Atria Investments LLC acquired a new stake in Ascendis Pharma A/S in the 1st quarter valued at $212,000. DekaBank Deutsche Girozentrale acquired a new stake in Ascendis Pharma A/S in the 1st quarter valued at $1,319,000. Victory Capital Management Inc. grew its position in Ascendis Pharma A/S by 51.6% in the 1st quarter. Victory Capital Management Inc. now owns 26,338 shares of the biotechnology company’s stock valued at $1,723,000 after purchasing an additional 8,970 shares during the period. Finally, Aperio Group LLC grew its position in Ascendis Pharma A/S by 46.5% in the 1st quarter. Aperio Group LLC now owns 10,059 shares of the biotechnology company’s stock valued at $658,000 after purchasing an additional 3,191 shares during the period. Institutional investors own 95.29% of the company’s stock.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Read More: Tariff

The Fly

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.